Astrazeneca Plc $AZN Shares Sold by Empire Financial Management Company LLC

Empire Financial Management Company LLC reduced its position in Astrazeneca Plc (NYSE:AZN) by 50.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,000 shares of the company’s stock after selling 6,000 shares during the period. Empire Financial Management Company LLC’s holdings in Astrazeneca were worth $1,183,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of AZN. Triumph Capital Management purchased a new stake in shares of Astrazeneca during the third quarter worth about $25,000. MV Capital Management Inc. purchased a new position in Astrazeneca in the fourth quarter valued at about $26,000. Mascoma Wealth Management LLC acquired a new stake in Astrazeneca during the 1st quarter valued at approximately $26,000. Bangor Savings Bank grew its stake in Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after purchasing an additional 154 shares in the last quarter. Finally, Eagle Bay Advisors LLC purchased a new stake in Astrazeneca during the 4th quarter worth approximately $30,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Astrazeneca Stock Performance

AZN stock opened at $172.41 on Wednesday. The stock’s 50 day simple moving average is $180.02 and its 200 day simple moving average is $187.95. Astrazeneca Plc has a 12-month low of $145.14 and a 12-month high of $212.71. The firm has a market cap of $267.39 billion, a P/E ratio of 25.77, a P/E/G ratio of 1.38 and a beta of 0.24. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last released its earnings results on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.13. The firm had revenue of $15.38 billion during the quarter, compared to analyst estimates of $15.44 billion. Astrazeneca had a net margin of 17.02% and a return on equity of 31.95%. The firm’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.17 earnings per share. As a group, equities research analysts predict that Astrazeneca Plc will post 10.22 EPS for the current year.

Astrazeneca News Roundup

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Quarterly earnings beat expectations: AstraZeneca reported adjusted EPS of $2.63, above the $2.50 consensus estimate. Revenue rose 6.4% year over year to $15.38 billion, narrowly missing expectations, while oncology, cardiovascular and rare-disease medicines helped offset generic competition. AstraZeneca beats second-quarter profit expectations, holds outlook
• Positive Sentiment: Full-year outlook maintained: Management backed its 2026 forecasts, helping reassure investors that strength in key growth franchises can offset weaker sales, product exclusivity pressure and challenges in China. AstraZeneca earnings beat forecasts despite slight revenue miss
• Positive Sentiment: Some analysts remain constructive: Citi raised its price target to 17,800 pence, citing AstraZeneca’s potential drug pipeline and long-term revenue ambitions. AstraZeneca’s drug pipeline is splitting opinion among City analysts
• Neutral Sentiment: Pricing strategy is changing: An executive said AstraZeneca is adjusting pricing for new U.S. drug launches in response to the Trump administration’s most-favoured-nation policy. The changes could affect future pricing and margins, but the financial impact remains uncertain. AstraZeneca drug prices evolving in response to Trump policy
• Negative Sentiment: Pipeline setback adds pressure: Rare-disease drug Ultomiris failed to meet the main goal in a late-stage trial involving a blood-vessel complication after stem-cell transplantation, renewing concerns about AstraZeneca’s longer-term growth pipeline. AstraZeneca’s rare disease drug misses main goal in late-stage trial
• Negative Sentiment: Analyst views are divided: Deutsche Bank reiterated a “sell” rating with an 11,500-pence valuation, highlighting uncertainty around pipeline execution and future growth. In addition, Pomerantz LLP announced an investigation into potential investor claims, which could create legal and reputational overhang. Pomerantz investor alert regarding AstraZeneca

Analyst Upgrades and Downgrades

AZN has been the topic of a number of recent analyst reports. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Finally, Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a research report on Monday, May 4th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Astrazeneca currently has an average rating of “Moderate Buy” and an average price target of $211.00.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.